Filing Flows › AIM ImmunoTech (AIM) › Q2 2026 › vs Q2 2025
AIM ImmunoTech (AIM) Q2 2026 vs Q2 2025 (year over year)
AIM ImmunoTech's revenue rose $1K (+4%) from $25K in Q2 2025 to $26K in Q2 2026.
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $26K | $25K | $1K | +4% |
| Net loss | $3.8M | $2.8M | $994K | +36% |
| Costs & expenses | $3.8M | $2.8M | $995K | +35% |
| Operating costs | $3.5M | $2.7M | $868K | +32% |
| Interest & other, net | $275K | $148K | $127K | +86% |
| Research & development | $589K | $1.2M | −$585K | -50% |
| General & admin | $2.9M | $1.5M | $1.5M | +98% |
| Operating cash sources | $4.6M | $1.6M | $3.0M | +192% |
| Depreciation & amortization | $44K | $55K | −$11K | -20% |
| Cash used in operations | $4.6M | $1.5M | $3.1M | +200% |
| Net loss absorbed | $3.8M | $2.8M | $994K | +36% |
| Working capital & other | $846K | −$1.2M | $2.1M | — |
Questions
How much did AIM ImmunoTech's revenue grow year over year in Q2 2026?
AIM ImmunoTech's revenue rose $1K (+4%) from $25K in Q2 2025 to $26K in Q2 2026.